Case reportPublished 17 Mar 2017
The Importance of EGFR Mutation Detection Method for the Correct Clinical Management of Patients with Non-Small Cell Lung Cancer: A Case Report
Department of Biomedical Sciences and Public Health, Pathologic Anatomy and Histopathology Division, Azienda Ospedaliero-Universitaria Ospedali Riuniti, Ancona, Italy; Medical Oncology Unit, S. Croce Hospital, Fano, Italy; Department of Immunoallergic and Respiratory Diseases, Pulmonary Diseases Unit, Azienda Ospedaliero-Universitaria Ospedali Riuniti, Ancona, Italy
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
In patients with non-small cell lung cancer (NSCLC), the naïve double EGFR mutation of exon 18 represents an unusual event and the few papers in the literature demonstrated the attenuated response to different tyrosine kinase inhibitors (TKIs). We presented a case of a 73-year-old female smoker patient with adenocarcinoma in the right upper lung lobe diagnosed in another Italian Hospital Center and the first molecular analysis, performed by the pyrosequencing platform in a cytological smear, identified a G719A mutation of EGFR gene. The patient was immediately treated with afatinib at a daily dose of 40 mg as TKI. During the normal follow up it was noted a partial response (PR) to treatment and, a new Computer Tomography, revealed the presence of an abnormal shadow in the right lower lung. A new Transbronchial Needle Aspiration (TBNA) and the consequent cyto-histological diagnosis revealed a relapse of the disease. A new molecular analysis made in our Center with Sequenom platform, showed a double EGFR mutation (G719A+E709A), both of exon 18. We also tested the EGFR with Sequenom platform in the cytological smear used for the first diagnosis, kindly sent us by Pathological Anatomy Unit of the Hospital Center, revealing both the double EGFR mutation G719A+E709A. Therefore, both mutations were the naïve double EGFR mutation of exon 18. This result explained the PR to afatinib treatment and highlighted the importance of multiplex and sensitive methods used to identify the correct EGFR activating mutations in NSCLC, on the right clinical management of these patients.
Subjects
Pathology & Lab MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Clinical & Experimental Pathology
- SubjectPathology & Lab Medicine
- BylineArticles whose byline prints “Zizzi A”
- BylineArticles whose byline prints “Barbisan F”
- BylineArticles whose byline prints “Laici G”
- BylineArticles whose byline prints “Postacchini E”
- BylineArticles whose byline prints “Biagiotti L”
- BylineArticles whose byline prints “Tozzo S”
- BylineArticles whose byline prints “Mei F”
- BylineArticles whose byline prints “Scarpelli M”